-
Clearside Biomedical NASDAQ:CLSD Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company's SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications.
Location: 900 N Point Pkwy Ste 200, Georgia, 30005-8995, US | Website: clearsidebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
102.7M
Cash
29.36M
Avg Qtr Burn
-4.778M
Short % of Float
0.26%
Insider Ownership
7.42%
Institutional Own.
26.33%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XIPERE (CLS-TA) Details Macular edema | Approved Quarterly sales | |
belzupacap saratalocan (bel-sar) (AU-011) Details Primary Choroidal Melanoma, Cancer | Phase 3 Data readout | |
CLS-AX Details Wet age-related macular degeneration , Age-related macular degeneration Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 2b Data readout | |
RGX-314 Details Wet age-related macular degeneration , Age-related macular degeneration | Phase 2 Update | |
ABBV-RGX-314 Details Diabetic retinopathy , Diabetic macular edema | Phase 2 Update |